Company profile for Talaris Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ. Talaris’ proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow tr...
Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ. Talaris’ proprietary technology allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs) safely from unmatched and unrelated donors, without the toxicity and risks of a traditional bone marrow transplant.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
93 Worcester Street Suite 120 Wellesley, MA 02481
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/10/19/2763751/0/en/Tourmaline-Bio-Announces-Closing-of-Merger-with-Talaris-Therapeutics-and-Concurrent-Private-Placement-of-75-Million.html

GLOBENEWSWIRE
19 Oct 2023

https://www.globenewswire.com//news-release/2023/10/17/2761965/0/en/Talaris-Therapeutics-Announces-Stockholder-Approval-of-Merger-with-Tourmaline-Bio.html

GLOBENEWSWIRE
17 Oct 2023

https://www.globenewswire.com//news-release/2023/10/06/2756329/0/en/Talaris-Therapeutics-Declares-Special-Dividend-In-Connection-with-Proposed-Merger-with-Tourmaline-Bio.html

GLOBENEWSWIRE
06 Oct 2023
Talaris CGT plants bulk out NYBCe CDMO biz
Talaris CGT plants bulk out NYBCe CDMO biz

06 Oct 2023

// BIOPROCESS INTERNATIONAL

https://bioprocessintl.com/bioprocess-insider/facilities-capacity/talaris-cgt-plants-bulk-out-nybce-cdmo-biz/

BIOPROCESS INTERNATIONAL
06 Oct 2023
Talaris Therapeutics to merge with Tourmaline Bio
Talaris Therapeutics to merge with Tourmaline Bio

23 Jun 2023

// Talaris Therapeutics PHARMACEUTICAL TECHNOLOGY

https://www.pharmaceutical-technology.com/news/talaris-therapeutics-tourmaline-bio/

Talaris Therapeutics PHARMACEUTICAL TECHNOLOGY
23 Jun 2023

https://endpts.com/tourmaline-bio-reverse-merges-into-talaris-joining-public-markets-and-targeting-thyroid-eye-disease/

Kyle LaHucik ENDPTS
22 Jun 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty